Huakang Biomedical Holdings Company Limited (8622.HK)
HKD 0.36
(-1.39%)
HKD 0.36
(-1.39%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 14.29 Million CNY | 44.73% |
| 2022 | 9.87 Million CNY | 5.59% |
| 2021 | 9.35 Million CNY | -13.72% |
| 2020 | 10.84 Million CNY | 35.07% |
| 2019 | 8.02 Million CNY | -35.33% |
| 2018 | 12.41 Million CNY | 12.52% |
| 2017 | 11.03 Million CNY | -16.72% |
| 2016 | 13.24 Million CNY | 13.1% |
| 2015 | 11.71 Million CNY | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 10.28 Million CNY | -28.03% |
| 2024 Q2 | 10.28 Million CNY | 0.0% |
| 2023 Q4 | 14.29 Million CNY | 0.0% |
| 2023 Q2 | 9.38 Million CNY | 0.0% |
| 2023 Q3 | - CNY | -100.0% |
| 2023 Q1 | - CNY | -100.0% |
| 2023 FY | 14.29 Million CNY | 44.73% |
| 2022 Q1 | - CNY | -100.0% |
| 2022 FY | 9.87 Million CNY | 5.59% |
| 2022 Q4 | 9.87 Million CNY | 0.0% |
| 2022 Q3 | - CNY | -100.0% |
| 2022 Q2 | 7.8 Million CNY | 0.0% |
| 2021 Q2 | 9.99 Million CNY | 0.0% |
| 2021 Q1 | - CNY | -100.0% |
| 2021 FY | 9.35 Million CNY | -13.72% |
| 2021 Q4 | 9.35 Million CNY | 0.0% |
| 2020 Q4 | 10.84 Million CNY | 0.0% |
| 2020 Q1 | - CNY | -100.0% |
| 2020 FY | 10.84 Million CNY | 35.07% |
| 2020 Q2 | 5.87 Million CNY | 0.0% |
| 2019 Q2 | 5.26 Million CNY | 0.0% |
| 2019 Q4 | 8.02 Million CNY | 0.0% |
| 2019 FY | 8.02 Million CNY | -35.33% |
| 2019 Q1 | - CNY | -100.0% |
| 2018 Q1 | - CNY | 0.0% |
| 2018 FY | 12.41 Million CNY | 12.52% |
| 2018 Q4 | 12.41 Million CNY | 0.0% |
| 2018 Q2 | 10.88 Million CNY | 0.0% |
| 2017 FY | 11.03 Million CNY | -16.72% |
| 2016 FY | 13.24 Million CNY | 13.1% |
| 2015 FY | 11.71 Million CNY | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Pak Fah Yeow International Limited | 142.28 Million HKD | 89.952% |
| Grand Pharmaceutical Group Limited | 7.24 Billion HKD | 99.803% |
| Extrawell Pharmaceutical Holdings Limited | 170.4 Million HKD | 91.611% |
| Wai Yuen Tong Medicine Holdings Limited | 709.65 Million HKD | 97.985% |
| Qianhai Health Holdings Limited | 94 Million HKD | 84.792% |
| Lee's Pharmaceutical Holdings Limited | 930.06 Million HKD | 98.463% |
| Essex Bio-Technology Limited | 903.78 Million HKD | 98.418% |
| Tongfang Kontafarma Holdings Limited | 665.38 Million HKD | 97.851% |
| PuraPharm Corporation Limited | 689.65 Million HKD | 97.927% |
| SSY Group Limited | 4.49 Billion HKD | 99.682% |
| JBM (Healthcare) Limited | 366.75 Million HKD | 96.102% |
| Jacobson Pharma Corporation Limited | 1.09 Billion HKD | 98.689% |
| China Resources Pharmaceutical Group Limited | 168.46 Billion HKD | 99.992% |